Open Outbreak

Mpox (clades I and II)

Pathogen: Monkeypox virus · Region: Worldwide · Status: active · Attention: elevated · Updated

OfficialMedia, unverifiedReported this week
Deaths—22 20 highest in the last 7 days—
Confirmed cases15,205 as of 31 Dec 2026101,872 1,058 highest in the last 7 days+4 Media, unverified
Suspected cases—1 as of 18 Sept 2026—

Official and media figures describe the same people from different vantage points and are never added together.

Mpox remains a live global watch item rather than a finished event. Official sources indicate that both clade II and clade I lineages, including clade Ib, are still circulating, with WHO no longer treating the situation as a Public Health Emergency of International Concern after 2025-09-05 but still publishing global updates and keeping a moderate risk assessment for higher-exposure sexual networks and a low risk assessment for the general population. In the last week of evidence, official or authority-linked updates included a new UK epidemiological overview, WHO Africa reporting expanded laboratory and sequencing capacity, and local surveillance bulletins in Mayotte and Angola showing continued case detection and response activity. The main uncertainty is not whether mpox still exists globally, but how much current transmission is being missed by fragmented reporting. WHO and public-health agencies frame the picture as persistent, heterogeneous transmission that needs targeted surveillance, testing, vaccination and case management. Media coverage often sounds more alarmed, emphasizing that mpox is “still spreading” or that individual national outbreaks are “worsening,” sometimes without the same risk stratification or without distinguishing local updates from global trend data. What would change the picture materially are sustained spread in new countries, clearer evidence that recombinant or clade Ib viruses are spreading more efficiently, rising severe disease in children or immunocompromised groups, or widening gaps between local bulletins and consolidated international reporting.

Mpox remains globally distributed, with persistent transmission and surveillance activity across multiple regions, but the retrieved evidence does not show a sharp new global acceleration this week. Risk stays elevated because human-to-human spread continues, severity can be substantial in some settings, and unusual strains are being watched, even though vaccines, testing and response tools exist.

Situation as of 14 Oct 2026

Official

WHO’s latest global framing available in this session is that mpox clades I and II continue to circulate globally. WHO said in its 2025 global situation update that the second mpox PHEIC was lifted on 2025-09-05, while clade Ib still posed a moderate public-health risk for men who have sex with men with new and/or multiple partners and a low risk for the general population. WHO also reported in February 2026 that recombinant viruses containing elements of clades Ib and IIb had been detected in two travel-associated cases. In the current month, WHO Africa reported expanded decentralized mpox testing, 46 of 47 Member States with sequencing capacity, and 51 laboratories across 32 countries participating in external quality assessment. The UK also issued an updated epidemiological overview on 2026-10-08, indicating continued formal monitoring.

Media, unverified

Recent press and authority-linked local coverage emphasizes persistence rather than a new global surge. Collected reports describe mpox as still spreading in the United States, worsening in South Africa, and continuing to generate local response activity in Angola and French overseas territories such as Mayotte and Réunion. These reports focus on country or territory narratives and public advice rather than a single consolidated global total.

Control measures

Current countermeasures shown in official material include decentralized PCR testing, genomic sequencing, surveillance bulletins, epidemiological overviews, case investigation, contact tracing, supportive clinical care, community engagement, and targeted vaccination where available. WHO continues to stress that vaccination should complement, not replace, broader public-health measures. No new broad travel restrictions were identified in the retrieved evidence.

Timeline

Latest reports

  1. · Rospotrebnadzor (Telegram) · Official
    Rospotrebnadzor is monitoring the monkeypox situation
  2. · TASS (EN) · Official
    Russia has enough test kits to diagnose mpox — Russia’s sanitary watchdog
  3. · TASS (EN) · Official
    Over 14,000 mpox cases confirmed worldwide in 2026 — Russia’s sanitary watchdog
  4. · TASS (EN) · Official
    Mpox continues spreading worldwide, Russia’s sanitary watchdog monitoring situation
  5. · TASS (Telegram) · Media, unverified
    Monkeypox continues to spread worldwide. Rospotrebnadzor is monitoring the situation, the agency said.
  6. · TASS (Telegram) · Media, unverified
    Monkeypox confirmed in five patients hospitalised in St. Petersburg on October 16. Their condition is stable, the press service of the S. P. Botkin Clinical Infectious Diseases Hospital told TASS.
  7. · TASS (Telegram) · Media, unverified
    Top news at this hour
  8. · Capital News · Media, unverified
    IGAD backs One Health drive to detect animal disease outbreaks before they reach humans
  9. · manilatimes.net · Media, unverified
    Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
  10. · manilatimes.net · Media, unverified
    Bavarian Nordic - Transactions in Connection with Share Buy - Back Program
  11. · SABC News · Media, unverified
    South Africa records four new Mpox cases, total rises to 26
  12. · fed.brid.gy · Social post, not counted
    WHO experts have backed targeted mpox vaccination and welcomed accelerated trials of #vaccines against #Ebola Bundibu…